Should targeted temperature management be used in cardiogenic shock patients? Systematic review and meta-analysis

Authors: Adam Nieborek, Jerzy R. Ladny, Milosz J. Jaguszewski, Andrea Denegri, Aleksandra Sikora, Szymon Pucylo, Aleksandra Gasecka, Michal Pruc, Ivan Savytsky, Lukasz Szarpak

DOI: 10.5603/CJ.a2022.0093
Article type: Original Article
Submitted: 2022-08-03
Accepted: 2022-08-30
Published online: 2022-10-04

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Cardiology Journal" are listed in PubMed.
Should targeted temperature management be used in cardiogenic shock patients? 
Systematic review and meta-analysis

Adam Nieborek et al., Targeted temperature management in cardiogenic shock

Adam Nieborek¹, Jerzy R. Ladny², Milosz J. Jaguszewski³, Andrea Denegri⁴, Aleksandra Sikora⁵, Szymon Pucylo⁵, Aleksandra Gasecka⁵, Michal Pruc⁶, Ivan Savytisky⁷, Lukasz Szarpak⁸,⁹,¹⁰

¹Research Unit, Polish Soviety of Disaster Medicine, Warsaw, Poland
²Clinic of Emergency Medicine, Medical University Bialystok, Poland
³First Department of Cardiology, Medical University of Gdansk, Poland
⁴Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Italy
⁵First Chair and Department of Cardiology, Medical University of Warsaw, Poland
⁶Research Unit, Polish Society of Disaster Medicine, Warsaw, Poland.
⁷European School of Medicine, International European University, Kyiv, Ukraine.
⁸Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, United States
⁹Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland
¹⁰Reseach Unit, Maria Sklodowska-Curie Bialysok Oncology Center, Bialystok, Poland

This paper was guest edited by Prof. Togay Evrin

Address for correspondence: Lukasz Szarpak, Assoc. Prof. PhD, DPH, DBA, MBA, Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Lubomirski Palace, ul. Żelazna Brama 10, 00–136 Warszawa, Poland, tel: +48 500 186 225, e-mail: lukasz.szarpak@gmail.com
Abstract

Background: Therapeutic hypothermia, or targeted temperature management (TTM), is a strategy of reducing the core body temperature of survivors of sudden cardiac arrest, cardiogenic shock (CS) or stroke. Therefore, a systematic literature review and meta-analysis were performed to tackle the question about whether the implementation of TTM is actually beneficial for patients with CS.

Methods: Study was designed as a systematic review and meta-analysis. PubMed, Cochrane Library, Web of Science and Scopus were searched from these databases inception to July 17, 2022. Eligible studies were those comparing TTM and non-TTM treatment in CS patients. Data were pooled with the Mantel-Haenszel method.

Results. Thirty-day mortality was reported in 3 studies. Polled analysis of 30-day mortality was 44.2% for TTM group and 48.9% for non-TTM group (risk ratio: 0.90; 95% confidence interval: 0.75 to 1.08; p = 0.27). Other mortality follow-up periods showed also no statistically significant differences (p > 0.05). The occurrence of adverse events in the studied groups also did not show statistically significant differences between TTM and non-TTM groups (p > 0.05 for myocardial infarction, stent thrombosis, sepsis, pneumonia, stroke or bleeding events).

Conclusions: The present analysis shows no significant benefit of TTM in patients with CS. Moreover, no statistically significant increase of the incidence of adverse effects was found. However, further randomized studies with higher sample size and greater validity are needed to determine if TTM is worth implementing in CS patients.

Key words: targeted temperature management, therapeutic hypothermia, cardiogenic shock, outcome, meta-analysis

INTRODUCTION

Cardiogenic shock (CS) is a life-threatening condition characterized by hypoxia and end-organ hypoperfusion, caused by severe impairment of the myocardium and diminished cardiac output [1]. With its mechanical complications, acute myocardial infarction (AMI) is responsible for most CS cases still burdened by significant mortality [2]. The persistence of high
mortality rates, varying from 38% to 65% [3, 4] is very distressing despite the fact that technical treatment of AMI complicated by CS has improved over the last decades [5].

In this regard, targeted temperature management (TTM) through therapeutic hypothermia (32°C – 34°C for 12 to 24 hours by surface cooling or endovascular cooling) has been investigated in several studies [6–9]. This level of hypothermia has a potentially neuroprotective effect [10, 11]. It works by reducing the brain’s metabolism and thus the oxygen, adenosine triphosphate, and glucose consumption, which are associated with reducing reperfusion injury [6, 9]. The large randomised controlled trial brought more evidence of the beneficial use of TTM in patients after cardiac arrest (CA) with no shockable rhythm, leading to a higher percentage of patients with a favourable neurologic outcome at day 90 [12].

According to current recommendations, TTM is the standard of care in adult patients with return of spontaneous circulation after out-of-hospital and in-hospital VF cardiac arrest [13–16]. A common complication after CA is fever, which has an incidence of 42%, and therefore TTM is effective in these patients [15, 16]. Randomized studies on porcine models showed possible benefits of TTM in CS with reduced acute mortality and hemodynamic parameter improvements [17, 18]. Unfortunately, this finding was not confirmed in humans [19].

Based on these assumptions, a systematic literature review and meta-analysis to tackle whether the implementation of TTM is beneficial for patients with CS was conducted herein.

**METHODS**

The systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement [20]. Due to study character (meta-analysis), ethical approval or patient consent was not suitable for this study.

**Literature search**

In this systematic review and meta-analysis, PubMed, Cochrane Library, Web of Science and Scopus was searched from these databases inception to July 17, 2022, for peer-reviewed original primary research articles, including observational or interventional studies, describing the outcomes of targeted temperature management in cardiogenic shock. For the search, the search term: “targeted temperature management” OR “TTM” OR “hypothermia” OR “therapeutic hypothermia” OR “mild hypothermia” AND “cardiogenic shock” OR “cardiogenic”...
OR “shock” was used. Additionally, manually checking the reference lists was done in each involved publication to identify eligible studies. Language and publication year restrictions were not applied. De-duplication and screening were carried out on EndNote software (X9; Claritive; Philadelphia, PA, USA).

**Inclusion and exclusion criteria**

Two reviewers (M.P. and L.S.) independently screened the titles and abstracts against the agreed inclusion criteria and then extracted and relevant full-text records were selected. Discrepancies were resolved through discussion at each stage by consensus. Two additional reviewers (M.J.J. and A.G.) verified the eligibility of inclusion of the studies when necessary. Studies that were included in this meta-analysis had to fulfil the following PICOS criteria: (1) Participants, patients with 18 years old or older with cardiogenic shock; (2) Intervention, targeted temperature management; (3) Comparison, non-TTM; (4) Outcomes, detailed information for survival or mortality; (5) Study design, randomized controlled trials (RCT) and observational trials (non-RCT) comparing TTM and non-TTM care for their effects in patients with cardiogenic shock. Studies were excluded if they were reviews, observational studies, animal studies, case reports, letters, conference or poster abstracts, or articles not containing original data.

**Data extraction**

Two reviewers (L.S. and M.P.) independently extracted data which were then checked for accuracy by a third reviewer (J.S.). Extracted data included: year of study, country, study design, patient demographics, and study outcomes. Mortality (within 30-days) was evaluated as the primary outcome. The secondary endpoint was major adverse cardiovascular and cerebrovascular events, i.e. a composite of death, myocardial infarction, stent thrombosis or stroke during a long-term observation period.

**Quality assessment**

Two reviewers (A.G. and M.P.) independently evaluated studies for risk of bias and quality assessment. Any disagreements were discussed and resolved in a consensus meeting with the third reviewer (L.S.). The RoB 2 tool (revised tool for risk of bias in randomized trials) was used to assess the quality of randomized studies [21], and the ROBINS-I tool (tool to determine
the risk of bias in non-randomized studies of interventions) was used to assess the quality of non-randomized trials [22]. The risk of bias assessments was visualized using the Robvis application [23].

**Statistical analyzes**

All statistical analyses were performed using Review Manager 5.4 Software (RevMan; The Cochrane Collaboration, Oxford, UK). An alpha criterion of a p-value less than 0.05 was considered statistically significant. Depending on the reported effect size measures, pooled risk ratios (RR), odds ratios (OD) or mean difference (MD), and 95% confidence intervals (CI) were calculated. When the continuous outcomes were reported in a study as median, range, and interquartile range, means and standard deviations were estimated using the formula described by Hozo et al. [24]. A random-effects approach (inverse variance or Mantel-Haenszel) was chosen to allow expected heterogeneity across the studies. The degree of heterogeneity among studies was based on the Cochrane Q statistics and I^2 statistics [25]. I^2 values of 50% or less corresponded to low to moderate, and 75% or higher indicated large amounts of heterogeneity.

**RESULTS**

The flow diagram describing study selection is shown in Figure 1. A total of 5 studies [19, 26–29] comprising of 580 patients met the inclusion criteria. They included patients with cardiogenic shock between 2012 and 2022. Table 1 displays the baseline characteristics between patients with CS with or without TTM.

No significant differences between two patient cohorts were observed in the age (68.7 ± 12.8 vs. 69.1 ± 12.7 years, respectively; MD: 0.18; 95% CI: –135 to 1.72; p = 0.81) or male gender (79.5% vs. 69.4%, respectively; OR: 1.36; 95% CI: 0.54 to 3.41; p = 0.52). Polled analysis of patient characteristics between TTM and non-TTM groups is shown in Suppl. Table S1). The results of the assessment of risk of bias among the 4 included studies is provided in Figure 2.

Thirty-day mortality was reported in three studies. Polled analysis of 30-day mortality was 47.8% for TTM group and 46.5% for non-TTM group (RR: 1.04; 95% CI: 0.78 to 1.39; p = 0.86). Other mortality follow-up periods showed also no statistically significant differences (p > 0.05). The occurrence of adverse events in the studied groups also did not show statistically significant
differences between TTM and non-TTM groups (p > 0.05 for myocardial infarction, stent thrombosis, sepsis, pneumonia, stroke or bleeding events). The detailed characteristics of the outcomes are presented in Table 2.

**DISCUSSION**

Despite early revascularization strategy and advanced treatment, AMI complicated by CS is still burdened by the high mortality rate. Therapeutic hypothermia has shown its efficacy in the treatment of CA, but recent evidence has not provided significant effectiveness of TTM in case of proceeding AMI complicated by CS. This meta-analysis aims to summarize knowledge of the subject matter.

Out of the 4 studies included in this meta-analysis [19, 26–29], three showed no significant clinical advantages of TTM therapy, with no benefit in terms of 30-day survival (47.8% vs. 46.5; RR: 1.04 [0.78–1.39]). The usefulness of TTM was investigated in several trials, but most of these studies were performed on a small number of patients. Oddo et al. [30] showed that TTM might improve patient outcomes, particularly in the short duration of CA. On the contrary, Noc et al. [31] demonstrated that the intravascular cooling system favored a longer ischemic delay with increased adverse events rate and no benefit in myocardial tissue protection.

During AMI, TTM may reduce infarct size when performed before reperfusion [32, 33]. However, when CS complicates AMI, outcomes did not show a significant difference compared to a control group (6.3% vs. 6.2%; RR: 1.01; 95% CI: 0.26 to 3.94; p = 0.96). In the TTM group, the only mild (but statistically insignificant) trend toward reduction of biochemical markers (creatine kinase, troponin T) was observed [26]. This may be due to a delayed cooling start time or measuring infarct size with biomarkers only.

Bleeding events and blood transfusions were also included in the analysis. One study showed a higher risk of TIMI significant bleedings (p = 0.07). However, most of them were related to the arterial catheterization access for percutaneous coronary intervention [27]. It is known that hypothermia causes coagulopathy with increased clotting time; this event is called hypothermic coagulopathy [34]. One Meta-Analysis of Randomized Controlled Trials [35], which consisted of 43 trials and included 7,528 patients, did not find an increased risk of hemorrhage in patients treated with TTM in general, despite a higher risk of thrombocytopenia and transfusion requirement for patients treated with TTM, particularly in those cooled longer.
than 48 hours. Thus, TTM should be performed for a maximum period of 24 hours. One study [27], included in the pooled analysis, suggested a potential higher incidence of stent thrombosis. However, several studies have shown that TTM in AMI patients undergoing percutaneous coronary intervention is safe and is not related to increased incidence of stent thrombosis [36, 37]. However, those studies did not include patients who had CS. An extensive retrospective analysis [38], including 49,109 CA patients with AMI undergoing PCI, considered 1,193 patients treated with TTM. This analysis showed that patients undergoing therapeutic hypothermia, who developed CS, presented a greater incidence of stent thrombosis compared with no TTM group (OR: 1.3; 95% CI: 1.0 to 1.6; p = 0.04). No other significant differences in the TTM group regarding stent thrombosis, bleeding events [39], arrhythmias, infection, coagulopathy, or hypotension [40] were observed.

Furthermore, an increased risk of sepsis and pneumonia was not found in the present study. Still, considering the studies that showed an increased risk of these adverse effects in other disease units, such as CA, caution should be exercised [41, 42].

To sum up, the pooled analysis of all 4 studies showed that using TTM in CS patients is safe. No evidence of excessive adverse events was found in the TTM group. The safety and feasibility of TTM are described in the literature associated with CA’s treatment [12, 43] and CS [44].

**Limitations of the study**

The findings of this analysis have to be seen in light of some limitations. Firstly, it must be stressed that it included only one randomized control trial. Some studies comprise a retrospective control group, and that increases the risk of bias.

Meaningful drawbacks include a small number of patients in each study who were additionally enrolled by different inclusion and exclusion criteria. It has caused that a part of studies excluded patients who underwent CA, whereas one study included them. Furthermore, one study based its inclusion criteria on the availability of a platelet function assessment. The SHOCK-COOL Trial by Fuernau et al. [19] does not describe any criteria because the trial was started before introducing the data-sharing policy. Zobel et al. [28] presents an analysis of patients who suffered from AMI and had only moderately reduced ejection fraction. Therefore, results could be different in patients with more severe compromised left ventricular function.
Cooling methods were also not consistent. The desired temperature was not reached in all patients in the TTM group. The duration of cooling in the majority of the studies was 24 hours — however, the odd one comprised 12 hours of the cooling procedure. The meaningful fact is that the standardization of cooling procedures is relevant, which cannot be seen in this review.

CONCLUSIONS

In summary, the present analysis shows no significant benefit of TTM in patients with CS. Moreover, no statistically significant increase was found in the incidence of adverse effects. However, further randomized studies with higher sample sizes and greater validity are needed to determine if TTM is worth implementing in CS patients.

Acknowledgments

The study was supported by the ERC Research Net and by the Polish Society of Disaster Medicine.

Conflict of interest: None declared

References


### Table 1. Characteristics of included trials.

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Study design</th>
<th>TTM group</th>
<th>Non-TTM group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>No</td>
<td>Age</td>
</tr>
<tr>
<td>Blatt et al. 2015</td>
<td>Israel</td>
<td>Prospective, open label</td>
<td>8</td>
<td>69.6 ±7.0</td>
</tr>
<tr>
<td>Fuernau et al. 2019</td>
<td>Germany</td>
<td>RCT</td>
<td>20</td>
<td>76.5 ±2.3</td>
</tr>
<tr>
<td>Levy et al. 2022</td>
<td>France</td>
<td>RCT</td>
<td>168</td>
<td>57 ±12</td>
</tr>
<tr>
<td>Orban et al. 2015</td>
<td>Germany</td>
<td>RCT</td>
<td>64</td>
<td>69.1 ±13</td>
</tr>
<tr>
<td>Zobel et al. 2012</td>
<td>Germany</td>
<td>Matched trial</td>
<td>20</td>
<td>59.5 ±15</td>
</tr>
</tbody>
</table>

*RCT* — randomized controlled trial; *TTM* — targeted temperature management

### Table 2. Pooled analysis of outcomes in targeted temperature management (TTM) and control groups.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>No. of studies</th>
<th>The frequency of occurrence</th>
<th>Events</th>
<th>Heterogeneity between trials</th>
<th>P-value for differences across groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>TTM</td>
<td>Control</td>
<td>RR</td>
<td>95%CI</td>
</tr>
<tr>
<td>Mortality:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30-days</td>
<td>4</td>
<td>44.2%</td>
<td>48.9%</td>
<td>0.90</td>
<td>0.75 to 1.08</td>
</tr>
<tr>
<td>6-months</td>
<td>1</td>
<td>52.4%</td>
<td>57.8%</td>
<td>0.91</td>
<td>0.75 to 1.10</td>
</tr>
<tr>
<td>1-year</td>
<td>1</td>
<td>75.0%</td>
<td>75.0%</td>
<td>1.00</td>
<td>0.70 to 1.43</td>
</tr>
<tr>
<td>2-years</td>
<td>1</td>
<td>65.0%</td>
<td>60.0%</td>
<td>1.08</td>
<td>0.67 to 1.75</td>
</tr>
<tr>
<td>Myocardial injury</td>
<td>1</td>
<td>6.3%</td>
<td>6.2%</td>
<td>1.01</td>
<td>0.26 to 3.94</td>
</tr>
<tr>
<td>Stent thrombosis</td>
<td>1</td>
<td>4.7%</td>
<td>0.0%</td>
<td>9.28</td>
<td>0.47 to 182.93</td>
</tr>
<tr>
<td>Sepsis</td>
<td>1</td>
<td>5.0%</td>
<td>0.0%</td>
<td>3.15</td>
<td>0.12 to 82.16</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>1</td>
<td>45.0%</td>
<td>30.0%</td>
<td>1.91</td>
<td>0.52 to 7.01</td>
</tr>
<tr>
<td>Stroke</td>
<td>2</td>
<td>3.6%</td>
<td>4.0%</td>
<td>0.85</td>
<td>0.19 to 3.91</td>
</tr>
<tr>
<td>Bleeding events or blood transfusion</td>
<td>3</td>
<td>42.5%</td>
<td>38.2%</td>
<td>1.18</td>
<td>0.83 to 1.67</td>
</tr>
</tbody>
</table>

*CI* — confidence interval; *NA* — not applicable; *RR* — risk ratio
Figure 1. Flow diagram showing stages of the database search and study selection as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Figure 2. A summary table of review author judgements for each risk of bias item for randomized trials (A) and non-randomized trials (B).
Records identified from: Databases (n = 312)

- Records removed before screening: Duplicate records removed (n = 71)

Records screened (n = 241)

- Records excluded based on titles and abstracts screening (n = 226)

Reports sought for retrieval (n = 15)

- Reports not retrieved (n = 0)

Reports assessed for eligibility (n = 15)

- Reports excluded (n = 10): Unusable results (n = 6) Non-comparative (n = 3) Review (n = 1)

Studies included in review (n = 5)
### A) Randomized trials

<table>
<thead>
<tr>
<th>Study</th>
<th>D1</th>
<th>D2</th>
<th>D3</th>
<th>D4</th>
<th>D5</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fuernau et al. 2019</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Levy et al. 2022</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Orban et al. 2015</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Domains:
- D1: Bias arising from the randomization process.
- D2: Bias due to deviations from intended intervention.
- D3: Bias due to missing outcome data.
- D4: Bias in measurement of the outcome.
- D5: Bias in selection of the reported result.

Judgement
- - Some concerns
- + Low

### B) Non-randomized trials

<table>
<thead>
<tr>
<th>Study</th>
<th>D1</th>
<th>D2</th>
<th>D3</th>
<th>D4</th>
<th>D5</th>
<th>D6</th>
<th>D7</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blatt et al. 2015</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Zobel et al. 2012</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

Domains:
- D1: Bias due to confounding.
- D2: Bias due to selection of participants.
- D3: Bias in classification of interventions.
- D4: Bias due to deviations from intended interventions.
- D5: Bias due to missing data.
- D6: Bias in measurement of outcomes.
- D7: Bias in selection of the reported result.

Judgement
- - Moderate
- + Low